PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
IBRX vs. BLUE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IBRX and BLUE is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

IBRX vs. BLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ImmunityBio, Inc. (IBRX) and bluebird bio, Inc. (BLUE). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-42.98%
-67.23%
IBRX
BLUE

Key characteristics

Sharpe Ratio

IBRX:

-0.10

BLUE:

-0.47

Sortino Ratio

IBRX:

0.75

BLUE:

-0.32

Omega Ratio

IBRX:

1.09

BLUE:

0.96

Calmar Ratio

IBRX:

-0.12

BLUE:

-0.71

Martin Ratio

IBRX:

-0.27

BLUE:

-1.29

Ulcer Index

IBRX:

42.61%

BLUE:

54.74%

Daily Std Dev

IBRX:

116.88%

BLUE:

151.95%

Max Drawdown

IBRX:

-97.14%

BLUE:

-99.80%

Current Drawdown

IBRX:

-92.38%

BLUE:

-99.73%

Fundamentals

Market Cap

IBRX:

$2.35B

BLUE:

$79.14M

EPS

IBRX:

-$0.99

BLUE:

-$36.00

Total Revenue (TTM)

IBRX:

$7.19M

BLUE:

$45.29M

Gross Profit (TTM)

IBRX:

$2.64M

BLUE:

-$21.31M

EBITDA (TTM)

IBRX:

-$224.31M

BLUE:

-$99.14M

Returns By Period

In the year-to-date period, IBRX achieves a 25.78% return, which is significantly higher than BLUE's -2.40% return.


IBRX

YTD

25.78%

1M

22.90%

6M

-43.01%

1Y

-11.78%

5Y*

-13.86%

10Y*

N/A

BLUE

YTD

-2.40%

1M

-4.24%

6M

-67.18%

1Y

-67.95%

5Y*

-63.10%

10Y*

-39.61%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IBRX vs. BLUE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBRX
The Risk-Adjusted Performance Rank of IBRX is 4444
Overall Rank
The Sharpe Ratio Rank of IBRX is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of IBRX is 5252
Sortino Ratio Rank
The Omega Ratio Rank of IBRX is 5050
Omega Ratio Rank
The Calmar Ratio Rank of IBRX is 3838
Calmar Ratio Rank
The Martin Ratio Rank of IBRX is 4040
Martin Ratio Rank

BLUE
The Risk-Adjusted Performance Rank of BLUE is 1717
Overall Rank
The Sharpe Ratio Rank of BLUE is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of BLUE is 2323
Sortino Ratio Rank
The Omega Ratio Rank of BLUE is 2424
Omega Ratio Rank
The Calmar Ratio Rank of BLUE is 77
Calmar Ratio Rank
The Martin Ratio Rank of BLUE is 1111
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IBRX vs. BLUE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ImmunityBio, Inc. (IBRX) and bluebird bio, Inc. (BLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for IBRX, currently valued at -0.10, compared to the broader market-2.000.002.004.00-0.10-0.47
The chart of Sortino ratio for IBRX, currently valued at 0.75, compared to the broader market-4.00-2.000.002.004.006.000.75-0.32
The chart of Omega ratio for IBRX, currently valued at 1.09, compared to the broader market0.501.001.502.001.090.96
The chart of Calmar ratio for IBRX, currently valued at -0.12, compared to the broader market0.002.004.006.00-0.12-0.71
The chart of Martin ratio for IBRX, currently valued at -0.27, compared to the broader market0.0010.0020.0030.00-0.27-1.29
IBRX
BLUE

The current IBRX Sharpe Ratio is -0.10, which is higher than the BLUE Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of IBRX and BLUE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-0.10
-0.47
IBRX
BLUE

Dividends

IBRX vs. BLUE - Dividend Comparison

Neither IBRX nor BLUE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IBRX vs. BLUE - Drawdown Comparison

The maximum IBRX drawdown since its inception was -97.14%, roughly equal to the maximum BLUE drawdown of -99.80%. Use the drawdown chart below to compare losses from any high point for IBRX and BLUE. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%AugustSeptemberOctoberNovemberDecember2025
-92.38%
-99.73%
IBRX
BLUE

Volatility

IBRX vs. BLUE - Volatility Comparison

ImmunityBio, Inc. (IBRX) and bluebird bio, Inc. (BLUE) have volatilities of 32.16% and 30.67%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%AugustSeptemberOctoberNovemberDecember2025
32.16%
30.67%
IBRX
BLUE

Financials

IBRX vs. BLUE - Financials Comparison

This section allows you to compare key financial metrics between ImmunityBio, Inc. and bluebird bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab